← Azimuth Daily
Capturing data…
Capturing data…
TUE, 20 OCT · 88 ITEMS
"MHRA authorises plozasiran (Redemplo) for familial chylomicronaemia syndrome" — Dept for Business and Trade · Science & Medicine
The UK Medicines and Healthcare products Regulatory Agency () has approved (brand name ) for treating (FCS), a rare inherited disorder that causes dangerously high levels of triglycerides in the blood. Plozasiran is an siRNA drug that targets the APOC3 gene to reduce triglyceride production, offering a new option for adults with this condition that often leads to pancreatitis and other complications.
The claim is based directly on an official MHRA press release, which is a primary source announcing the regulatory decision. As such, it is authoritative regarding the fact of authorisation, though specific clinical details would require reading the full release or underlying trial data.
Genuinely new: the authorisation was announced on 19 October 2026, as confirmed by the grounding window and the press release's publication date.